Endothelial progenitor dysfunction associates with a type i interferon signature in primary antiphospholipid syndrome

Annals of the Rheumatic Diseases

Volumn 76, Issue 2, 2017, Pages 450-457

  Grenn, Robert C ^a   Yalavarthi, Srilakshmi ^a   Gandhi, Alex A ^a   Kazzaz, Nayef M ^a   Núñez Álvarez, Carlos ^b   Hernández Ramírez, Diego ^b   Cabral, Antonio R ^b,c   McCune, W Joseph ^a   Bockenstedt, Paula L ^a   Knight, Jason S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Antiphospholipid Syndrome; Atherosclerosis; Cytokines

Indexed keywords

INTERFERON; NEUTRALIZING ANTIBODY; ALPHA BETA INTERFERON RECEPTOR; ALPHA INTERFERON; IFNAR2 PROTEIN, HUMAN;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CELL FUNCTION; COHORT ANALYSIS; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANTAGONISTS AND INHIBITORS; CASE CONTROL STUDY; CELL DIFFERENTIATION; DRUG EFFECTS; FLOW CYTOMETRY; IMMUNOLOGY; MIDDLE AGED; MONONUCLEAR CELL; PATHOPHYSIOLOGY; PHYSIOLOGY; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, NEUTRALIZING; ANTIPHOSPHOLIPID SYNDROME; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; ENDOTHELIAL PROGENITOR CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE I; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RECEPTOR, INTERFERON ALPHA-BETA; YOUNG ADULT;

EID: 84978743210     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209442     Document Type: Article

References (55)

1. Denny MF, Thacker S, Mehta H, et al. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 2007;110:2907-15.
2. Fadini GP, Sartore S, Albiero M, et al. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol 2006;26:2140-6.
3. Grisar J, Aletaha D, Steiner CW, et al. Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 2005;111:204-11.
4. Rehman J, Li J, Orschell CM, et al. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003;107:1164-9.
5. Kawamoto A, Gwon HC, Iwaguro H, et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 2001;103:634-7.
6. Fadini GP. A reappraisal of the role of circulating (progenitor) cells in the pathobiology of diabetic complications. Diabetologia 2014;57:4-15.
7. Kachamakova-Trojanowska N, Bukowska-Strakova K, Zukowska M, et al. The real face of endothelial progenitor cells-Circulating angiogenic cells as endothelial prognostic marker? Pharmacol Rep 2015;67:793-802.
8. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964-7.
9. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005;353:999-1007.
10. Kahlenberg JM, Thacker SG, Berthier CC, et al. Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. J Immunol 2011;187:6143-56.
11. Urbich C, Aicher A, Heeschen C, et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 2005;39:733-42.
12. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019-27.
13. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (Aca) directed not to cardiolipin but to a plasma-protein cofactor. Lancet 1990;335:1544-7.
14. McNeil HP, Simpson RJ, Chesterman CN, et al. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta-2-glycoprotein-I (apolipoprotein-H). Proc Natl Acad Sci USA 1990;87:4120-4.
15. Ruiz-Irastorza G, Crowther M, Branch W, et al. Antiphospholipid syndrome. Lancet 2010;376:1498-509.
16. Yalavarthi S, Gould TJ, Rao AN, et al. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. Lancet 2015;67:2990-3003.
17. Leffler J, Stojanovich L, Shoenfeld Y, et al. Degradation of neutrophil extracellular traps is decreased in patients with antiphospholipid syndrome. Clin Exp Rheumatol 2014;32:66-70.
18. Abreu MM, Danowski A, Wahl DG, et al. The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev 2015;14:401-14.
19. Denas G, Jose SP, Bracco A, et al. Antiphospholipid syndrome and the heart: a case series and literature review. Autoimmun Rev 2015;14:214-22.
20. Amaya-Amaya J, Rojas-Villarraga A, Anaya JM. Cardiovascular disease in the antiphospholipid syndrome. Lupus 2014;23:1288-91.
21. Bilora F, Sartori MT, Zanon E, et al. Flow-mediated arterial dilation in primary antiphospholipid syndrome. Angiology 2009;60:104-7.
22. Der H, Kerekes G, Veres K, et al. Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome. Lupus 2007;16:497-503.
23. Jiménez S, García-Criado MA, T?ssies D, et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford) 2005;44:756-61.
24. Margarita A, Batuca J, Scenna G, et al. Subclinical atherosclerosis in primary antiphospholipid syndrome. Ann N Y Acad Sci 2007;1108:475-80.
25. Stalc M, Poredos P, Peternel P, et al. Endothelial function is impaired in patients with primary antiphospholipid syndrome. Thromb Res 2006;118:455-61.
26. Gresele P, Migliacci R, Vedovati MC, et al. Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. Thromb Res 2009;123:444-51.
27. Ambrosino P, Lupoli R, Di Minno A, et al. Markers of cardiovascular risk in patients with antiphospholipid syndrome: a meta-analysis of literature studies. Ann Med 2014;46:693-702.
28. Kaplan MJ, Salmon JE. How does interferon-alpha insult the vasculature? Let me count the ways. Arthritis Rheum 2011;63:334-6.
29. Somers EC, Zhao W, Lewis EE, et al. Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS ONE 2012;7:e37000.
30. Lee PY, Li Y, Richards HB, et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 2007;56:3759-69.
31. Rodríguez-Carrio J, de Paz B, López P, et al. IFNalpha serum levels are associated with endothelial progenitor cells imbalance and disease features in rheumatoid arthritis patients. PLoS ONE 2014;9:e86069.
32. Mohan S, Barsalou J, Bradley TJ, et al. Endothelial progenitor cell phenotype and function are impaired in childhood-onset systemic lupus erythematosus. PLoS ONE 2015;67:2257-62.
33. Thacker SG, Duquaine D, Park J, et al. Lupus-prone New Zealand Black/New Zealand White F1 mice display endothelial dysfunction and abnormal phenotype and function of endothelial progenitor cells. Lupus 2010;19:288-99.
34. Knight JS, Zhao W, Luo W, et al. Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. J Clin Invest 2013;123:2981-93.
35. Thacker SG, Berthier CC, Mattinzoli D, et al. The detrimental effects of IFN-alpha on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J Immunol 2010;185:4457-69.
36. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
37. Kirou KA, Lee C, George S, et al. Coordinate overexpression of interferon-alphainduced genes in systemic lupus erythematosus. Arthritis Rheum 2004;50:3958-67.
38. Seeds RE, Gordon S, Miller JL. Characterisation of myeloid receptor expression and interferon alpha/beta production in murine plasmacytoid dendritic cells by flow cytomtery. J Immunol Methods 2009;350:106-17.
39. Perez-Sanchez C, Barbarroja N, Messineo S, et al. Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus. Ann Rheum Dis 2015;74:1441-9.
40. Erkan D, Willis R, Murthy VL, et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis 2014;73:1176-80.
41. Armañanzas R, Calvo B, Inza I, et al. Microarray analysis of autoimmune diseases by machine learning procedures. IEEE Trans Inf Technol Biomed 2009;13:341-50.
42. Gómez-Puerta JA, Martín H, Amigo MC, et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore) 2005;84:225-30.
43. Ramos-Casals M, Campoamor MT, Chamorro A, et al. Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients. Lupus 2004;13:777-83.
44. Niewold TB, Rivera TL, Buyon JP, et al. Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus. Arthritis Rheum 2008;58:541-6.
45. Kirou KA, Lee C, George S, et al. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005;52:1491-503.
46. Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011;3:73ra20.
47. Villanueva E, Yalavarthi S, Berthier CC, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 2011;187:538-52.
48. Hashimoto Y, Kawamura M, Ichikawa K, et al. Anticardiolipin antibodies in NZW× BXSB F1 mice. A model of antiphospholipid syndrome. J Immunol 1992;149:1063-8.
49. Balderramo DC, García O, Colmenero J, et al. Antiphospholipid syndrome during pegylated interferon alpha-2a therapy for chronic hepatitis C. Dig Liver Dis 2009;41: e4-7.
50. Gressier L, Guilpain P, Gorin I, et al. Skin necrosis revealing antiphospholipid syndrome during immunotherapy for melanoma. Acta Derm Venereol 2010;90:433-4.
51. Shinohara MM, Davis C, Olerud J. Concurrent antiphospholipid syndrome and cutaneous [corrected] sarcoidosis due to interferon alfa and ribavirin treatment for hepatitis C. J Drugs Dermatol 2009;8:870-2.
52. Erdmann J, Vitale G, van Koetsveld PM, et al. Effects of interferons alpha/beta on the proliferation of human micro- and macrovascular endothelial cells. J Interferon Cytokine Res 2011;31:451-8.
53. Pammer J, Reinisch C, Birner P, et al. Interferon-alpha prevents apoptosis of endothelial cells after short-term exposure but induces replicative senescence after continuous stimulation. Lab Invest 2006;86:997-1007.
54. Kalunian KC, Merrill JT, Maciuca R, et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis 2016;75:196-202.
55. Crow MK, Olferiev M, Kirou KA. Targeting of type I interferon in systemic autoimmune diseases. Transl Res 2015;165:296-305.